Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) EBT (2018 - 2025)

Historic EBT for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$708991.0.

  • BioNexus Gene Lab's EBT rose 4724.04% to -$708991.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year decrease of 15787.71%. This contributed to the annual value of -$1.6 million for FY2024, which is 3883.65% up from last year.
  • Latest data reveals that BioNexus Gene Lab reported EBT of -$708991.0 as of Q3 2025, which was up 4724.04% from -$616172.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's EBT registered a high of $370491.0 during Q3 2021, and its lowest value of -$2.5 million during Q3 2023.
  • Over the past 5 years, BioNexus Gene Lab's median EBT value was -$83689.0 (recorded in 2024), while the average stood at -$284824.1.
  • Per our database at Business Quant, BioNexus Gene Lab's EBT skyrocketed by 269619.29% in 2021 and then tumbled by 366413.13% in 2023.
  • Over the past 5 years, BioNexus Gene Lab's EBT (Quarter) stood at $197077.0 in 2021, then tumbled by 164.67% to -$127451.0 in 2022, then surged by 298.96% to $253571.0 in 2023, then tumbled by 266.44% to -$422032.0 in 2024, then plummeted by 67.99% to -$708991.0 in 2025.
  • Its EBT was -$708991.0 in Q3 2025, compared to -$616172.0 in Q2 2025 and -$623327.0 in Q1 2025.